BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26707798)

  • 21. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
    Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
    Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcript level of nucleostemin in newly diagnosed acute myeloid leukemia patients.
    You Y; Li X; Zheng J; Wu Y; He Y; Du W; Zou P; Zhang M
    Leuk Res; 2013 Dec; 37(12):1636-41. PubMed ID: 24119536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.
    Sun YX; Kong HL; Liu CF; Yu S; Tian T; Ma DX; Ji CY
    Hum Immunol; 2014 Feb; 75(2):113-8. PubMed ID: 24269703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications].
    Yu MX; Lu Y; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):544-8. PubMed ID: 24078567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
    Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
    Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.
    Aref S; Salama O; Al-Tonbary Y; Mansour A
    Hematology; 2004 Apr; 9(2):113-21. PubMed ID: 15203866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of NF-kappaB mRNA in acute myeloid leukemia].
    Liu M; Wei XD; Lü XD; Fan RH; Yin QS; Zhou J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):359-62. PubMed ID: 20416168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.